RBC Capital Maintains Outperform on Guardant Health, Raises Price Target to $200
Benzinga Newsdesk 3 months ago
Analyst RatingsNewsPrice Target
RBC Capital analyst Dan Leonard maintains Guardant Health (NASDAQ:GH) with a Outperform and raises the price target from $185 to $200.
RBC Capital analyst Dan Leonard maintains Guardant Health (NASDAQ:GH) with a Outperform and raises the price target from $185 to $200.